Pertuzumab Study: Breast Cancer

Title: A Randomized, Double-Blind, Multicenter, Parallel Group, Clinical Trial to Compare Efficacy, Safety and Immunogenicity of Intas Pertuzumab with Perjeta® (In combination with Trastuzumab and Docetaxel) in Patients with HER2-Positive Metastatic Breast Cancer.